Last --
Change Today 0.00 / 0.00%
Volume 0.0
1093 On Other Exchanges
Symbol
Exchange
1093 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

cspc pharmaceutical group lt (1093) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CSPC PHARMACEUTICAL GROUP LT (1093)

Related News

No related news articles were found.

cspc pharmaceutical group lt (1093) Related Businessweek News

No Related Businessweek News Found

cspc pharmaceutical group lt (1093) Details

CSPC Pharmaceutical Group Limited, an investment holding company, manufactures and sells pharmaceutical products. It offers finished drugs, including NBP series primarily for the acute ischemic stroke; Oulaining series primarily for the treatment of mild to moderate memory and mental impairment resulting from vascular dementia, senile dementia, and brain trauma; Xuanning principally for hypertension; Duomeisu, a chemotherapy drug; Jinyouli for the prevention of leucopenia and infection induced by chemotherapy; and Ailineng primarily for the treatment of nerve glioma and brain metastases, and adjuvant treatment of malignant pleural and peritoneal effusion. The company also provides generic drugs, antibiotics, vitamin C products, and caffeine and other drugs. In addition, it researches and develops approximately 170 products for therapeutic areas of anti-infective, cardio-cerebrovascular, diabetes, neurology, and oncology. Further, the company offers pharmaceutical research and development services; and sewage treatment services. It has operations primarily in the People’s Republic of China, other Asian regions, the Americas, and Europe. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. The company is based in Wan Chai, Hong Kong and is considered a Red Chip company due to its listing on the Hong Kong Stock Exchange.

10,390 Employees
Last Reported Date: 04/9/14

cspc pharmaceutical group lt (1093) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $10.8M
Executive Director
Total Annual Compensation: $3.9M
Executive Director
Total Annual Compensation: $760.0K
Executive Director
Total Annual Compensation: $760.0K
Executive Director
Total Annual Compensation: $760.0K
Compensation as of Fiscal Year 2013.

cspc pharmaceutical group lt (1093) Key Developments

CSPC Pharmaceutical Group Limited Receives Phase II/ III Clinical Trial Approval for Mitoxantrone Hydrochloride Liposome Injection

The board of directors of CSPC Pharmaceutical Group Limited announced that the phase I clinical trial data of ‘mitoxantrone hydrochloride liposome injection’ developed by the Group has passed the technical assessment of the Centre for Drug Evaluation of China Food and Drug Administration of the People's Republic of China, and was recently granted the approval for phase II/III clinical trial (Approval no.: 2014L02412). Mitoxantrone hydrochloride is an anthracycline broad-spectrum antibiotic, mainly used in malignant tumour treatment. The active ingredient of the Product is mitoxantrone hydrochloride. Its liposome injection formulation has less side effects such as bone marrow inhibition and cardiac toxication as compared to conventional injection formulation, and also possesses certain specific advantages, including i) slow and continuous drug release, prolonging the effective time of the drug; ii) significant reduction in distribution of drug among healthy tissue or organs, which in turns lower the toxicity of the drug; and iii) leveraging on the targeting effect of liposome, efficacy is enhanced with the drug concentrating on tumour tissue. Non clinical trial results suggest: i) as compared to conventional mitoxantrone formulation, the Product has the characteristics of long circulation and demonstrating linear kinetics inside human body and will not accumulate between two administrations; ii) the Product is tumour targeted, as compared to the same dosage of conventional formulation, it has a lower concentration and less distribution of mitoxantrone in the majority of the healthy tissue (heart, kidney, lung, spleen and intestine tissue) and a higher concentration and more distribution of mitoxantrone in the tumour tissue; iii) as compared to conventional mitoxantrone formulation, the Product demonstrates a better anti-tumour activity in several animal tumour models with a therapeutic index of more than 20 times higher, it is also better than the conventional formulation in the safety aspect. Phase I clinical trial results suggest: i) the Product has good safety and tolerance when applying to patients with malignant tumour once or multiple times by intravenous infusion within 6~16mg/m 2 (higher dosage is currently undergoing research), with no adverse event and no dose-limiting toxicity in this research; ii) the adverse effects of 16mg/m 2 liposome injection is far less than those of 10mg/m 2 conventional injection; iii) during the observation period of preliminary treatment, among both of the 14mg/m 2 and 16mg/m 2 groups (3 participants in each group), there is 1 case of complete response (complete disappearance of tumour in imaging examination) after 3 weeks of treatment for patients with non-Hodgkin lymphomas, showing a certain degree of efficacy. The Group has submitted Pre-IND application to the U.S. Food and Drug Administration of the Product and has obtained a positive written opinion in December 2014 from the U.S. FDA. It is expected that the formal Investigational New Drug application could be submitted in the second half of 2015. The Group has applied Patent Cooperation Treaty (PCT) patent for the Product. Currently, authorization was granted in China, Europe, Canada, Russia, Australia, Korea and Singapore. Its applications in USA and Japan have entered into the assessment stage and authorization is expected to be granted soon. Mitoxantrone hydrochloride liposome injection has not yet launched in the world. Based on the good clinical and non clinical research results, the Group will endeavor to launch the Product in order to benefit patients with tumour across and outside the country.

CSPC Pharmaceutical Group Limited Presents at Hong Kong and China Corporate Day, Jan-21-2015

CSPC Pharmaceutical Group Limited Presents at Hong Kong and China Corporate Day, Jan-21-2015 . Venue: Mandarin Oriental Hotel, Hong Kong.

CSPC Pharmaceutical Group Limited Presents at UBS 15th Greater China Conference, Jan-12-2015

CSPC Pharmaceutical Group Limited Presents at UBS 15th Greater China Conference, Jan-12-2015 . Venue: Pudong Island Shangri-La, Shanghai, China.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1093:HK $6.64 HKD +0.06

1093 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1093.
View Industry Companies
 

Industry Analysis

1093

Industry Average

Valuation 1093 Industry Range
Price/Earnings 34.6x
Price/Sales 3.7x
Price/Book 5.2x
Price/Cash Flow 34.3x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSPC PHARMACEUTICAL GROUP LT, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.